糖皮质激素作为脓毒症辅助治疗的现代角色
本文回顾了1976至2017年间22项随机安慰剂对照试验,这些试验评估糖皮质激素在社区获得性肺炎、脓毒症和脓毒性休克中的获益,结果相互矛盾。2018年两项大型RCT(APROCCHSS和ADRENAL)分别报告氢化可的松对脓毒性休克90天死亡率有降低和无获益,本文对这两项RCT进行批判性评价,并评估糖皮质激素在现代脓毒症和脓毒性休克治疗中的应用。
要点
- 糖皮质激素用于脓毒症辅助治疗已超过四十年,但其获益仍存争议。
- 2018年APROCCHSS与ADRENAL两项RCT在脓毒性休克患者中得出相反死亡率结论。
- 本文对上述两项RCT进行批判性评价,探讨现代脓毒症治疗中糖皮质激素的定位。
核心结论
- 糖皮质激素在脓毒症和脓毒性休克中的辅助治疗作用需结合2018年两项大型RCT的差异进行批判性评估。
研究设计与样本
- 本文为观点类文章,批判性评价APROCCHSS和ADRENAL两项大型RCT,并回顾1976至2017年间22项随机安慰剂对照试验。
主要发现
- 1976至2017年间22项随机安慰剂对照试验评估糖皮质激素在社区获得性肺炎、脓毒症和脓毒性休克中的获益,结果相互矛盾。
- APROCCHSS试验报告氢化可的松降低脓毒性休克患者90天死亡率。
- ADRENAL试验报告氢化可的松对脓毒性休克患者无死亡率获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucocorticoids have been used as adjunctive therapy in patients with sepsis and septic shock for more than four decades. The rationale for the use of glucocorticoids is that this class of drugs downregulates the proinflammatory response and limits the anti-inflammatory response while preserving innate immunity. Between 1976 and 2017, 22 randomised placebo-controlled trials have been published evaluating the benefit of glucocorticoids in patients with community-acquired pneumonia, sepsis, and septic shock. These studies produced conflicting results. In 2018, two large randomised controlled trials (RCTs) were published evaluating the role of hydrocortisone in patients with septic shock. The Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial reported a reduction in 90-day mortality whereas the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) trial reported no mortality benefit. This Viewpoint critically appraises these two RCTs and evaluates the use of glucocorticoids in the treatment of sepsis and septic shock in the modern era.
引用
- Marik PE. The role of glucocorticoids as adjunctive treatment for sepsis in the modern era. Lancet Respir Med. 2018. PMID: 30006071. doi:10.1016/S2213-2600(18)30265-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。